– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment.
Recursion, Canaan, Metsera and more—Chutes & Ladders fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) has been given an average rating of “Hold” by the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year target […]
Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) hit a new 52-week high on Tuesday . The stock traded as high as $24.31 and last traded at $24.30, with a volume of 2308369 shares. The stock had previously closed at $24.30. Wall Street Analyst Weigh In PRVB has been the topic of several recent research reports. […]